Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and human...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Nat Commun
Auteurs principaux: Cross, Robert W., Bornholdt, Zachary A., Prasad, Abhishek N., Geisbert, Joan B., Borisevich, Viktoriya, Agans, Krystle N., Deer, Daniel J., Melody, Kevin, Fenton, Karla A., Feldmann, Heinz, Sprecher, Armand, Zeitlin, Larry, Geisbert, Thomas W.
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7385100/
https://ncbi.nlm.nih.gov/pubmed/32719371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-17446-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires